| Literature DB >> 31234440 |
Martina O Chukwu1, Akebe Luther King Abia2, Eunice Ubomba-Jaswa3,4, Lawrence Obi5, John Barr Dewar1.
Abstract
Antibiotic-resistant Campylobacter could adversely affect treatment outcomes, especially in children. We investigated the antibiotic susceptibility profiles, virulence potentials and genetic relatedness of Campylobacter spp. from paediatric and water samples in the North West Province, South Africa. Overall, 237 human and 20 water isolates were identified using culture and real-time polymerase chain reaction (PCR). The antibiotic susceptibility profiles were determined using the disk diffusion method. Gradient strips were used to determine the minimum inhibitory concentration of each antibiotic. Antibiotic resistance (gryA, tetO and 23S rRNA 2075G and 2074C) and virulence (cadF and ciaB) genes were also investigated using PCR. A phylogenetic tree to ascertain the clonality between water and clinical isolates was constructed using MEGA 7. Overall, 95% (water) and 64.7% (human) of the isolates were resistant to at least one antibiotic tested. The highest resistance was against clarithromycin (95%) for water and ampicillin (60.7%) for human isolates. The 23S rRNA 2075G/2074C mutation was the most expressed resistance gene. Phylogenetic reconstruction revealed eight intermixed clades within water and human Campylobacter isolates. This study suggests the possible circulation of potentially pathogenic antibiotic-resistant Campylobacter in the Northwest Province, South Africa with drinking water being a possible vector for disease transmission in this area.Entities:
Keywords: Campylobacter spp.; antibiotic susceptibility profile; household drinking water; paediatric diarrhoea; phylogenetic analysis; resistance genes; virulence genes
Mesh:
Substances:
Year: 2019 PMID: 31234440 PMCID: PMC6617328 DOI: 10.3390/ijerph16122205
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Primers used for virulence and resistance genes.
| Target Gene | Primer Name | Sequence (5′–3′) | Size (bp) | Reference |
|---|---|---|---|---|
|
| cadF-F2B | CTAATACCTAAAGTTGAAAC | 400 | [ |
|
| ciaB-652 | TGCGAGATTTTTCGAGAATG | 527 | [ |
|
| GyrAF1 | CAACTGGTTCTAGCCTTTTG | 210 | [ |
|
| TetO | GTGACATCTTTTCAGTGGGAGG | 1014 | [ |
| 23SRNA-F | TTAGCTAATGTTGCCCGTACCG | 486 | [ | |
| 23SRNA-F | TTAGCTAATGTTGCCCGTACCG | 485 | [ |
Distribution of Campylobacter spp. based on water source and point of collection.
| Water Source | No. of Samples Collected | No. of |
|
|
|
|---|---|---|---|---|---|
| Direct Tap water | 8 | 0 | 0 | 0 | 0 |
| Stored Tap water | 38 | 5 (13.2%) | 2 (10%) | 2 (10%) | 1 (5%) |
| Stored well water | 42 | 15 (35.7%) | 9 (45%) | 6 (30%) | 0 |
| River water | 4 | 0 | 0 | 0 | 0 |
| Total | 92 | 20 (21.7%) | 11 (55%) | 8 (40%) | 1 (5%) |
Antimicrobial resistance profile of human Campylobacter isolates.
| Class of Antibiotic | Antibiotics | Code | Conc. (µg) | No. Resistant (%) | |
|---|---|---|---|---|---|
| Human Samples | WATER Samples | ||||
| Macrolides | Clarithromycin | CLR | 15 | 44 (29.3) | 19 (95) |
| Erythromycin | ERY | 15 | 40 (26.7) | 17 (85) | |
| Carbapenem | Meropenem | MEM | 10 | 29 (19.3) | 3 (15) |
| Imipenem | IPM | 10 | 23 (15.3) | 0 | |
| β-lactam/β-lactamase inhibitor combination | Amoxicillin/clavulanic acid | AMX | 30 | 97 (64.7) | 6 (30) |
| Penicillin | Ampicillin | AMP | 2 | 91 (60.7) | 14 (70) |
| Fluoroquinolones | Ciprofloxacin | CIP | 5 | 27 (18) | 5 (25) |
| Norfloxacin | NOR | 10 | 17 (13.3) | 8 (40) | |
| Aminoglycosides | Amikacin | AMK | 30 | 27 (18) | 8 (40) |
| Gentamicin | GEN | 10 | 23 (15.3) | 9 (45) | |
| Tetracycline | Tetracycline | TET | 30 | 48 (32) | 11 (55) |
| Tigecycline | TGC | 15 | 45 (30) | 9 (45) | |
| Cephalosporine | Cephazolin | CFZ | 30 | 90 (60) | 10 (50) |
| Cefuroxime | CXM | 30 | 81 (54) | 7 (35) | |
Note: EUCAST interpretation criteria for erythromycin on C. jejuni (˂20) and C. coli (˂24) was used in interpreting results for the macrolides. CLSI breakpoint for Enterobacteriaceae was used for aminoglycosides, carbapenems and fluoroquinolones.
Antimicrobial resistance rates of C. jejuni, C. coli and C. upsaliensis from clinical specimens.
| Antibiotics |
|
|
| |||
|---|---|---|---|---|---|---|
| Human Samples ( | Water Samples ( | Human Samples ( | Water Samples ( | Human Samples ( | Water Samples ( | |
| Clarithromycin | 19 (28.7%) | 10 (90.9%) | 21 (35.5%) | 8 (100%) | 4 (16%) | 0 |
| Erythromycin | 15 (22.7%) | 11 (100%) | 21 (35.5%) | 6 (75%) | 4 (16%) | 0 |
| Meropenem | 9 (13.6%) | 1 (9%) | 16 (27%) | 2 (25%) | 4 (16%) | 0 |
| Imipenem | 8 (12%) | 0 | 13 (22%) | 0 | 2 (8%) | 0 |
| Amoxicillin/clavulanic acid | 44 (66.6%) | 4 (36.4%) | 36 (61%) | 2 (25%) | 17 (68%) | 0 |
| Ampicillin | 40 (60.6%) | 10 (90.9%) | 37 (62.7%) | 5 (62.5%) | 14 (68%) | 1 (100%) |
| Ciprofloxacin | 16 (24.2%) | 1 (9%) | 11 (18.6%) | 3 (37.5%) | 0 | 1 (100%) |
| Norfloxacin | 11 (16.6%) | 2 (18%) | 5 (8.4%) | 5 (62.5%) | 1 (4%) | 1 (100%) |
| Amikacin | 16 (24.2%) | 4 (36.4%) | 10 (16.9%) | 3 (37.5%) | 1 (4%) | 1 (100%) |
| Gentamicin | 14 (21.2%) | 4 (36.4%) | 9 (15.2%) | 4 (50%) | 0 | 1 (100%) |
| Tetracycline | 24 (36.3%) | 3 (27.3%) | 19 (32.2%) | 6 (75%) | 5 (20%) | 1 (100%) |
| Tigecycline | 24 (36.3%) | 3 (27.3%) | 16 (32.2%) | 6 (75%) | 5 (20%) | 1 (100%) |
| Cephazolin | 41 (62%) | 5 (45.5%) | 35 (59.3%) | 4 (50%) | 14 (56%) | 1 (100%) |
| Cefuroxime | 33 (50%) | 2 (18%) | 37 (62.7%) | 4 (50%) | 11 (44%) | 1 (100%) |
Distribution of MIC amongst the clinical Campylobacter isolates.
| Antibiotics/MIC |
|
|
| |||
|---|---|---|---|---|---|---|
| Human | Water | Human | Water | Human | Water | |
| Erythromycin | 16 (24.4%) | 10 (90%) | 22 (37.2%) | 5 (62.5%) | 4 (16%) | 0 |
| Ciprofloxacin | 11 (16.6%) | 1 (9%) | 10 (16.9%) | 3 (37.5%) | 0 | 1 (100%) |
| Tetracycline | 19 (28%) | 3 (27.3%) | 11 (18.6%) | 6 (75%) | 4 (16%) | 1 (100%) |
| Ampicillin | 37 (56%) | 10 (90.9%) | 29 (49%) | 5 (62.5%) | 14 (56%) | 1 (100%) |
| Gentamicin | 14 (21.2%) | 4 (36.45) | 6 (10%) | 4 (50%) | 0 | 1 (100%) |
Figure 1The overall percentage of multi-antibiotic resistance of Campylobacter isolates.
Distribution of antibiotic resistance genes in Campylobacter isolates.
| Species |
| Human Samples | Water Sample | |||||
|---|---|---|---|---|---|---|---|---|
| Mutation at A2074C/A2075G (%) |
| Mutation at A2074C/A2075G (%) | ||||||
|
| 91 | 18 (19.7%) | 29 (31.8) | 17 (18.6) | 11 | 1 (9) | 3 (27.3) | 8 (72.7) |
|
| 81 | 14 (17.2) | 25 (30.8) | 20 (24.6) | 8 | 3 (37) | 5 (62.5) | 6 (75) |
|
| 34 | 6 (17.6) | 5 (14.7) | 3 (8.8) | 1 | 1 (100) | 0 | 1 (100) |
| Total 206 | 206 | 38 (18.4) | 59 (28.6) | 40(19.4) | 20 | 5 (25) | 8 (40) | 15 (75) |
Distribution of virulence genes according to Campylobacter species.
| Human Samples | Water Samples | |||||
|---|---|---|---|---|---|---|
|
|
| |||||
|
| 108 | 40 (37) | 59 (54.6) | 11 | 8 (72.7) | 10 (90.9) |
|
| 89 | 35 (39.3) | 48 (53.9) | 8 | 7 (87.5) | 6 (75) |
|
| 40 | 15 (37.5) | 14 (35) | 1 | 1(100) | 1 (100) |
| Total | 237 | 90 (38) | 121 (51) | 20 | 16 (80) | 17 (85) |
Figure 2Phylogenetic tree displaying relatedness between human and water isolates.